Fate therapeutics announces fda clearance of ind application for first-ever ipsc-derived car t-cell therapy

Fate therapeutics announces fda clearance of ind application for first-ever ipsc-derived car t-cell therapy.fate therapeutics inc - phase 1 clinical study will evaluate ft819 for patients with advanced b-cell leukemias and lymphomas.

FATE Ratings Summary

FATE Quant Ranking